Advanced search
1 file | 13.26 MB

Skin, mucosal and blood-brain barrier kinetics of model cyclic depsipeptides : the mycotoxins beauvericin and enniatins

Lien Taevernier (UGent)
(2016)
Author
Promoter
(UGent)
Organization
Abstract
This research takes off by giving an introduction to the wonderful world of the chemically very diverse cyclic depsipeptides (CDPs). This family of compounds is biosynthetically produced by an extreme variety of natural organisms, such as bacteria and fungi, which can be found all over the world. CDPs exhibit multiple biological activities, serving as interesting drug leads for the development of medicines. For the first time a classification system for CDPs was introduced. Some CDPs synthesised by fungi, however, can also be toxic and are potentially harmful. In scientific literature, there is a lack of a clear definition for these so-called mycotoxins, although very important for risk analyses. Therefore, we presented a new, quantitative expressed ‘mycotoxin’ definition, by means of the philosophical concept of explication. Recently, beauvericin and enniatins are recognised as ‘emerging’ mycotoxins. Exposure to these CDPs should not be considered as trivial, given their potential biological effects and presence as food and feed contaminants. Subsequent to the successful development of a bioanalytical method for the determination of beauvericin and enniatins in diverse matrices, their kinetic transport across the skin, oral mucosal and blood-brain barrier was quantitatively evaluated. Finally, a pharmaceutical preparation, containing enniatins as active ingredient and used in the treatment of upper respiratory tract infections, was investigated. Because of the negative risk-benefit ratio, we questioned its use in these innocent respiratory infections. For the same reason, the European Medicines Agency (EMA) has very recently endorsed the recall of these medicines from the European market.
Keywords
mucosa, blood-brain barrier, skin, barrier permeation kinetics, classification, cyclic depsipeptides, enniatins, mycotoxins, beauvericin

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 13.26 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Taevernier, Lien. 2016. “Skin, Mucosal and Blood-brain Barrier Kinetics of Model Cyclic Depsipeptides : the Mycotoxins Beauvericin and Enniatins”. Ghent, Belgium: Ghent University. Faculty of Pharmaceutical Sciences.
APA
Taevernier, L. (2016). Skin, mucosal and blood-brain barrier kinetics of model cyclic depsipeptides : the mycotoxins beauvericin and enniatins. Ghent University. Faculty of Pharmaceutical Sciences, Ghent, Belgium.
Vancouver
1.
Taevernier L. Skin, mucosal and blood-brain barrier kinetics of model cyclic depsipeptides : the mycotoxins beauvericin and enniatins. [Ghent, Belgium]: Ghent University. Faculty of Pharmaceutical Sciences; 2016.
MLA
Taevernier, Lien. “Skin, Mucosal and Blood-brain Barrier Kinetics of Model Cyclic Depsipeptides : the Mycotoxins Beauvericin and Enniatins.” 2016 : n. pag. Print.
@phdthesis{8079864,
  abstract     = {This research takes off by giving an introduction to the wonderful world of the chemically very diverse cyclic depsipeptides (CDPs). This family of compounds is biosynthetically produced by an extreme variety of natural organisms, such as bacteria and fungi, which can be found all over the world. CDPs exhibit multiple biological activities, serving as interesting drug leads for the development of medicines. For the first time a classification system for CDPs was introduced. Some CDPs synthesised by fungi, however, can also be toxic and are potentially harmful. In scientific literature, there is a lack of a clear definition for these so-called mycotoxins, although very important for risk analyses. Therefore, we presented a new, quantitative expressed {\textquoteleft}mycotoxin{\textquoteright} definition, by means of the philosophical concept of explication. Recently, beauvericin and enniatins are recognised as {\textquoteleft}emerging{\textquoteright} mycotoxins. Exposure to these CDPs should not be considered as trivial, given their potential biological effects and presence as food and feed contaminants. Subsequent to the successful development of a bioanalytical method for the determination of beauvericin and enniatins in diverse matrices, their kinetic transport across the skin, oral mucosal and blood-brain barrier was quantitatively evaluated. Finally, a pharmaceutical preparation, containing enniatins as active ingredient and used in the treatment of upper respiratory tract infections, was investigated. Because of the negative risk-benefit ratio, we questioned its use in these innocent respiratory infections. For the same reason, the European Medicines Agency (EMA) has very recently endorsed the recall of these medicines from the European market.},
  author       = {Taevernier, Lien},
  isbn         = {9789461974372},
  language     = {eng},
  pages        = {278},
  publisher    = {Ghent University. Faculty of Pharmaceutical Sciences},
  school       = {Ghent University},
  title        = {Skin, mucosal and blood-brain barrier kinetics of model cyclic depsipeptides : the mycotoxins beauvericin and enniatins},
  year         = {2016},
}